Hemorrhagic Stroke Research Unit, Section of Neurosurgery, University of Chicago Medicine and Biological Sciences, IL 60637, USA.
Curr Cardiol Rep. 2012 Dec;14(6):754-60. doi: 10.1007/s11886-012-0316-4.
Intracranial hemorrhage (ICH) accounts for 10-15 % of all strokes, however it causes 30-50 % of stroke related mortality, disability and cost. The prevalence increases with age with only two cases/100,000/year for age less than 40 years to almost 350 cases/100,000/year for age more than 80 years. Several trials of open surgical evacuation of ICH have failed to show clear benefit over medical management. However, some small trials of minimal invasive hematoma evacuation in combination with thrombolytics have shown encouraging results. Based on these findings larger clinical trials are being undertaken to optimize and define therapeutic benefit of minimally invasive surgery in combination with thrombolytic clearance of hematoma. In this article we will review some of the background of minimally invasive surgery and the use of thrombolytics in the setting of ICH and intraventricular hemorrhage (IVH) and will highlight the early findings of MISTIE and CLEAR trials for these two entities respectively.
颅内出血 (ICH) 占所有中风的 10-15%,但它导致 30-50%的中风相关死亡率、残疾和费用。随着年龄的增长,患病率增加,40 岁以下的年龄每 10 万人中只有 2 例,而 80 岁以上的年龄每 10 万人中几乎有 350 例。几项开颅手术清除 ICH 的试验未能显示出明显优于药物治疗的效果。然而,一些微创血肿清除术联合溶栓治疗的小型试验显示出令人鼓舞的结果。基于这些发现,正在进行更大规模的临床试验,以优化和确定微创血肿清除术联合溶栓治疗的疗效。本文将回顾微创神经外科学的一些背景以及溶栓药物在 ICH 和脑室内出血 (IVH) 中的应用,并将重点介绍 MISTIE 和 CLEAR 试验在这两种情况下的早期发现。